Conjugated Estrogens (Premarin)

Category:

  • Hormonal  

Description:

  • Estrogen hormone

Indications:

  • Menopausal vasomotor symptoms (hot flashes, etc.)

  • Atrophic vaginitis and kraurosis vulvae

  • Female hypogonadism

  • Female castration and primary ovarian failure

  • Breast cancer (palliation only)

  • Prostatic carcinoma

  • Osteoporosis prophylaxis

  • Postpartum breast engorgement

  • Abnormal uterine bleeding due to hormonal imbalance

Contraindications:

  • Known or suspected breast cancer (except those being treated for metastatic disease)

  • Known or suspected estrogen-dependent neoplasia

  • Known or suspected pregnancy

  • Undiagnosed abnormal genital bleeding

  • Current or history of thrombophlebitis, thrombosis, thromboembolic disorders (except when used in breast or prostatic cancer treatment).

Precautions:

  • Pregnancy category X

  • Use with caution in nursing mothers and patients with hypertension, diabetes, asthma, epilepsy, migraine, cardiac or renal dysfunction, history of depression, pre-existing uterine leiomyotoma, history of jaundice during pregnancy, impaired liver function, metabolic bone disorders and in young women (and men).

  • Take with food to avoid GI side effects.

  • May decrease glucose intolerance in diabetic patients.

  • Discontinue therapy and contact health care provider if pregnancy is suspected.

Adverse Reactions (Side Effects):

  • Rash, acne, alopecia, hirsutism

  • Abnormal menstrual bleeding, changes in cervical secretions

  • Edema, weight change

  • Depression, insomnia, somnolence

  • Nausea

Dosage:

  • Administered orally, vaginally and IV injection

  • Menopausal vasomotor symptoms: 1.25mg per day

  • Atrophic vaginitis and kraurosis vulvae: 0.3-1.25mg orally, intravaginally and topically per day depending on tissue response

  • Female hypogonadism: 2.5-7.5mg per day in divided doses for 20 days, then rest for ten days, then repeat schedule until bleeding occurs

  • Female castration and primary ovarian failure: 1.25mg per day cyclically, adjusted to lowest dose for individual

  • Breast cancer (palliation only): 10mg tid for at least three months

  • Prostatic carcinoma: 1.25-2.5mg tid

  • Osteoporosis prophylaxis: 1.25mg per day, cyclically

  • Postpartum breast engorgement: 3.75mg q4h for 5 doses or 1.25mg q4h for 5 days

  • Abnormal uterine bleeding due to hormonal imbalance: 25mg IM or IV injection, repeat in 6-12 hours if needed

For more information on the use of conjugated estrogens, read:

 

Home  ·  Military Medicine  ·  Sick Call  ·  Basic Exams  ·  Medical Procedures  ·  Lab and X-ray  ·  The Pharmacy  ·  The Library  ·  Equipment  ·  Patient Transport  ·  Medical Force Protection  ·  Operational Safety  ·  Operational Settings  ·  Special Operations  ·  Humanitarian Missions  ·  Instructions/Orders  ·  Other Agencies  ·  Video Gallery  ·  Forms  ·  Web Links  ·  Acknowledgements  ·  Help  ·  Feedback

Approved for public release; Distribution is unlimited.

The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks.

Source: Operational Medicine 2001, Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300.

Bureau of Medicine and Surgery
Department of the Navy
2300 E Street NW
Washington, D.C
20372-5300

Operational Medicine
 Health Care in Military Settings
CAPT Michael John Hughey, MC, USNR
NAVMED P-5139
  January 1, 2001

United States Special Operations Command
7701 Tampa Point Blvd.
MacDill AFB, Florida
33621-5323

*This web version is provided by The Brookside Associates, LLC.  It contains original contents from the official US Navy NAVMED P-5139, but has been reformatted for web access and includes advertising and links that were not present in the original version. The medical information presented was reviewed and felt to be accurate in 2001. Medical knowledge and practice methods may have changed since that time. Some links may no longer be active. This web version has not been approved by the Department of the Navy or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. The Brookside Associates is a private organization, not affiliated with the United States Department of Defense.

© 2015, Brookside Associates, LLC. All rights reserved

Other Brookside Products

 

 

Advertise on this site